Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Osteoporosis is a condition in which the amount of bone is reduced, the bones are weak, and there is an increased risk for fractures. Glucocorticoids (such as prednisone) are prescribed to treat a large number of conditions such as arthritis and asthma. When taken for several months or longer, glucocorticoids can cause bone loss and lead to a form of osteoporosis called "glucocorticoid-induced osteoporosis." This study compared the effects of teriparatide, the study drug, with alendronate, an approved drug for treating glucocorticoid-induced osteoporosis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Alendronate; Glucocorticoids; Teriparatide

Criteria

Inclusion Criteria:

• Men or women age 21 years or older

• Taking on average 5.0 mg/day prednisone or equivalent for at least 3 months prior to screening

Exclusion Criteria:

• Taking bisphosphonates within past 6 months

• More than 30 micrograms/day of estradiol or equivalent in past 3 months

• History of alcoholism or drug abuse in past year

• Pregnant women or nursing mothers